 | Up a level |
2020
Berthold, F., Faldum, A., Ernst, A., Boos, J., Dilloo, D., Eggert, A., Fischer, M., Fruehwald, M., Henze, G., Klingebiel, T., Kratz, C., Kremens, B., Krug, B., Leuschner, I, Schmidt, M., Schmidt, R., Schumacher-Kuckelkorn, R., von Schweinitz, D., Schilling, F. H., Theissen, J., Volland, R., Hero, B. and Simon, T. (2020). Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR. Ann. Oncol., 31 (3). S. 422 - 430. AMSTERDAM: ELSEVIER. ISSN 1569-8041
2018
Nemes, K., Kachanov, D., Simon, T., Hauser, P., Tippelt, S., Woessmann, W., Flotho, C., Grigulls, L., Hernaiz-Driever, P., Schlegel, P. G., Abbink, F., Gi-da-Costa, M. J., Lowis, S., Hernandes Marquez, C., Graf, N., Nysom, K., Bens, S., Kroencke, T., Furtwaengler, R. and Fruehwald, M. (2018). Clinical and Genetic Risk Factors Define Two Risk Groups of Extracranial Rhabdoid Tumors: A Plea for High Risk Tailored Therapies. Pediatr. Blood Cancer, 65. S. S57 - 1. HOBOKEN: WILEY. ISSN 1545-5017
2016
Corbacioglu, S., Lode, H., Escherich, G., Grigull, L., Hundsdoerfer, P., Steinbach, D., Schilling, F., Fruehwald, M., Greil, J., Gruhn, B., Ladenstein, R., Roessig, C. and Thorsten, S. (2016). RIST-RNB-2011: A Prospective Randomized Multicenter Trial of a Molecularly Targeted Multimodal Strategy for Patients with Relapsed and Refractory Neuroblastoma: An Update of the Ongoing Trial. Pediatr. Blood Cancer, 63. S. S209 - 1. HOBOKEN: WILEY-BLACKWELL. ISSN 1545-5017